> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Harvard Drug Recalls Drugs Due to Mislabeling
- URL: https://www.fdaweb.com/harvard-drug-recalls-drugs-due-to-mislabeling/
- Published: 2023-06-16T12:00:00.000Z
- Updated: 2026-09-14T18:39:41.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154707

The Harvard Drug Group is recalling a single lot of dronabinol capsules (2.5 mg) and ziprasidone hydrochloride capsules (20 mg) after receiving a customer complaint from a distributor suggesting that some unit dose cartons labeled as ziprasidone were found to contain blister packages labeled as and containing dronabinol.

Patients who mistakenly take dronabinol instead of ziprasidone can experience serious adverse events due to missing their ziprasidone dose and taking an unexpected dose of dronabinol, a recall [notice](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/harvard-drug-group-llc-issues-voluntary-nationwide-recall-dronabinol-capsules-usp-25-mg-and?utm%5Fmedium=email&utm%5Fsource=govdelivery) says. “Patients missing doses of ziprasidone can experience an exacerbation of underlying health issues such as bipolar disorder, schizophrenia, agitation, aggression, or delirium,” it says. “Taking an unexpected dose of dronabinol may cause mental and cognitive effects that result in impairment of mental and/or physical abilities. This can include worsening of symptoms in patients with mental illness disorders and limitation of patients’ abilities to safely complete hazardous activities (e.g., driving a motor vehicle, operating machinery).”